Abivax KOL Investor Event: Review of Phase 2b Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis
About The Event
Join Abivax for a virtual KOL investor event featuring Marla Dubinsky, MD (Professor of Pediatrics and Medicine, Icahn School of Medicine Mount Sinai New York, Chief, Pediatric GI and Nutrition, Mount Sinai Kravis Children’s Hospital) and Parambir Dulai, MD (Director of GI Clinical Trials and Precision Medicine, Director Digestive Health Foundation Biorepository Associate Professor of Medicine, Division of Gastroenterology and Hepatology Feinberg School of Medicine, Northwestern University), who, along with company management, will discuss the unmet medical need and current treatment landscape for patients with ulcerative colitis (UC).
The event will also highlight the ongoing and future clinical development plans for Obefazimod, Abivax’s lead drug candidate, and include a review of the Phase 2b clinical data and Phase 3 trial design for the treatment of adults with moderately to severely active UC. Obefazimod is an oral small molecule with a novel mechanism of action that demonstrates enhanced expression of miR-124, which plays a critical role in the regulation of the inflammatory response.
A live question and answer session will follow the formal presentations.